scispace - formally typeset
Open AccessJournal ArticleDOI

Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables

Reads0
Chats0
TLDR
In this article, the authors evaluated clinical, pathologic, and molecular outcome indicators and stratification models in a cohort (n = 207) of patients with medulloblastoma 3 to 16 years of age from the International Society of Pediatric Oncology CNS9102 (PNET3) trial.
Abstract
Purpose Medulloblastomas are heterogeneous and include relatively good-prognosis tumors characterized by Wnt pathway activation, as well as those that cannot be successfully treated with conventional therapy. Developing a practical therapeutic stratification that allows accurate identification of disease risk offers the potential to individualize adjuvant therapy and to minimize long-term adverse effects in a subgroup of survivors. Methods Using formalin-fixed paraffin-embedded (FFPE) tissue for immunohistochemistry, fluorescent in situ hybridization, and direct sequencing to identify tumors with a Wnt pathway signature and those harboring copy number abnormalities (CNAs) of potential prognostic significance (MYC/MYCN amplification, CNAs of chromosome 6 and 17), we evaluated clinical, pathologic, and molecular outcome indicators and stratification models in a cohort (n = 207) of patients with medulloblastoma 3 to 16 years of age from the International Society of Pediatric Oncology CNS9102 (PNET3) trial. R...

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Medulloblastomics: the end of the beginning

TL;DR: The availability of next-generation sequencing and complementary high-density genomic technologies has unmasked novel driver mutations in each medulloblastoma subgroup, pinpointing previously unappreciated diagnostic and therapeutic targets.
Journal ArticleDOI

Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups

TL;DR: A robust method for detecting SHH, WNT, and non-SHH/WNT molecular subgroups in formalin-fixed medulloblastoma samples is described and the first outcome data based on a clinical trial cohort and novel data on how molecular sub groups are distributed across the range of disease are provided.
References
More filters

An Introduction to Recursive Partitioning Using the RPART Routines

TL;DR: The tree is constructed: Splitting criteria, building the tree, variable importance, and more.
Journal ArticleDOI

Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

TL;DR: An encouraging EFS rate for children with nondisseminated MB treated with reduced-dose craniospinal radiation and chemotherapy is disclosed and additional, careful, step-wise reductions in CSRT in adequately staged patients may be possible.
Journal ArticleDOI

Genomics Identifies Medulloblastoma Subgroups That Are Enriched for Specific Genetic Alterations

TL;DR: Genome-wide expression profiles can partition large tumor cohorts into subgroups that are enriched for specific genetic alterations that may assist ultimately in the selection of patients for future clinical trials of molecular targeted therapies.
Related Papers (5)